Atrial Fibrillation

Atrial fibrillation is a common sustained cardiac arrhythmia associated with increased risks of ischemic stroke, heart failure, hospitalization, and reduced quality of life. Its burden is shaped by ageing, hypertension, obesity, diabetes, sleep-disordered breathing, valvular disease, and other cardiovascular conditions. Effective management requires coordinated assessment of thromboembolic risk, symptom burden, ventricular rate, rhythm, comorbidities, and patient preferences.

Clinical practice is moving from episodic treatment toward earlier detection and integrated long-term management. Wearable sensors, ambulatory monitoring, implantable devices, and opportunistic screening can identify previously unrecognized episodes, while contemporary care increasingly combines stroke prevention, risk-factor modification, rate control, rhythm control, and follow-up. Catheter ablation and other rhythm-management approaches are being considered earlier for appropriate patients, although access, clinical capacity, and patient selection remain important constraints.

Artificial intelligence is being applied to electrocardiogram interpretation, prediction of atrial fibrillation from sinus-rhythm recordings, analysis of wearable data, and identification of patients who may benefit from additional monitoring. These tools may support earlier recognition and help prioritize clinical review, but their usefulness depends on representative training data, external validation, transparent performance measures, interoperability, and clinician oversight. Privacy, false positives, algorithmic bias, and unclear accountability remain material implementation considerations.

North America emphasizes guideline-based anticoagulation, advanced rhythm management, remote monitoring, and technology-enabled care, while affordability and uneven access remain relevant. Latin America faces variation in diagnosis, specialist availability, anticoagulant access, and management of rheumatic and hypertensive heart disease. Europe benefits from established clinical guidelines and coordinated health systems, but differences in reimbursement and service capacity persist. The Middle East is balancing rapid adoption of advanced care with substantial cardiometabolic risk. Africa requires stronger screening, referral pathways, workforce capacity, and access to essential medicines. Asia-Pacific spans highly developed electrophysiology services alongside settings where diagnosis, continuity of care, and rural access remain limited.

ASEAN countries differ substantially in health-system maturity, urban–rural access, and availability of electrophysiology expertise, making scalable screening and primary-care integration important. BRICS members face large and diverse populations, heterogeneous insurance arrangements, and varying access to diagnostics and anticoagulation. The European Union must address cross-border consistency, data governance, and unequal procedural availability. G7 health systems generally have stronger specialist infrastructure but must manage ageing populations, workforce pressure, and care costs. GCC countries are investing in advanced services while addressing cardiometabolic risk and reliance on concentrated specialist capacity. NATO members require resilient cardiovascular services, interoperable records, and continuity of care across differing national systems.

Australia is positioned to expand remote monitoring while addressing geographic access; Brazil needs stronger primary-care detection and equitable specialist referral; Canada must manage regional variation and wait times; China is combining digital health adoption with large-scale prevention needs; France and Germany are focusing on coordinated guideline implementation and capacity; India requires affordable diagnostics, risk-factor control, and broader specialist access; Italy and Spain must address ageing, comorbidity, and regional service differences; Japan faces substantial ageing-related demand and workforce considerations; Mexico needs earlier diagnosis and continuity across fragmented care; Russia requires consistent access to diagnostics and evidence-based prevention; South Korea is advancing digital and specialist care while managing population ageing; the United Kingdom continues to emphasize case finding, integrated pathways, and reduction of avoidable stroke; and the United States combines advanced treatment options with persistent disparities in affordability and access.

Leaders should develop solutions around validated clinical needs rather than technology novelty. Priorities include reliable detection linked to clear referral pathways, interoperable data exchange, patient-centered anticoagulation support, integrated risk-factor management, and earlier access to rhythm-control services when clinically appropriate. Organizations should validate artificial-intelligence tools across diverse populations, monitor real-world safety and equity, provide transparent outputs, and preserve clinician accountability. Partnerships with health systems, primary-care networks, regulators, and patient groups can improve implementation, while workforce training and access-sensitive service design can reduce geographic and socioeconomic gaps.

This executive summary is based on a structured synthesis of established clinical knowledge regarding atrial fibrillation, associated risk factors, diagnostic approaches, treatment pathways, digital health, and regional health-system conditions. Findings are organized comparatively across the specified regions, groups, and countries. The assessment emphasizes reproducible, clinically relevant themes and excludes unsupported numerical claims, market estimates, forecasts, market shares, and company-specific conclusions. Interpretation should be updated as guidelines, regulatory requirements, technologies, and population-health evidence evolve.

Atrial fibrillation care is increasingly defined by prevention, timely detection, individualized stroke-risk management, and coordinated control of symptoms and comorbidities. Digital monitoring and artificial intelligence can extend clinical reach, but they must be embedded in validated pathways with appropriate oversight. Across regions and country groups, the central opportunity is to connect primary care, diagnostics, specialist services, and long-term follow-up while improving equitable access to proven interventions.